Search Results - "LORCH, Jochen H"

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial by Kaufman, Howard L, Prof, Russell, Jeffery, MD, Hamid, Omid, MD, Bhatia, Shailender, MD, Terheyden, Patrick, MD, D'Angelo, Sandra P, MD, Shih, Kent C, MD, Lebbé, Céleste, Prof, Linette, Gerald P, MD, Milella, Michele, MD, Brownell, Isaac, MD, Lewis, Karl D, MD, Lorch, Jochen H, MD, Chin, Kevin, MD, Mahnke, Lisa, MD, von Heydebreck, Anja, PhD, Cuillerot, Jean-Marie, MD, Nghiem, Paul, Prof

“…Summary Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in patients with advanced disease. Current standard care uses…”
Get full text

Genomic analysis of metastatic cutaneous squamous cell carcinoma by Li, Yvonne Y, Hanna, Glenn J, Laga, Alvaro C, Haddad, Robert I, Lorch, Jochen H, Hammerman, Peter S

“…A rare 5% of cutaneous squamous cell carcinomas (cSCC) metastasize, lack FDA-approved therapies, and carry a poor prognosis. Our aim was to identify recurrent…”
Get full text

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer by Wagle, Nikhil, Grabiner, Brian C, Van Allen, Eliezer M, Amin-Mansour, Ali, Taylor-Weiner, Amaro, Rosenberg, Mara, Gray, Nathanael, Barletta, Justine A, Guo, Yanan, Swanson, Scott J, Ruan, Daniel T, Hanna, Glenn J, Haddad, Robert I, Getz, Gad, Kwiatkowski, David J, Carter, Scott L, Sabatini, David M, Jänne, Pasi A, Garraway, Levi A, Lorch, Jochen H

“…After a prolonged response, an anaplastic thyroid cancer developed resistance to mammalian target of rapamycin (mTOR) inhibition by somatic mutation of mTOR at…”
Get full text

Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial by Lorch, Jochen H, Dr, Goloubeva, Olga, PhD, Haddad, Robert I, MD, Cullen, Kevin, Prof, Sarlis, Nicholas, MD, Tishler, Roy, MD, Tan, Ming, Prof, Fasciano, John, Sammartino, Daniel E, BSc, Posner, Marshall R, Prof

“…Summary Background At a minimum follow-up of 2 years, the TAX 324 study showed a significant survival benefit of induction chemotherapy with docetaxel,…”
Get full text

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial by Kaufman, Howard L, Russell, Jeffery S, Hamid, Omid, Bhatia, Shailender, Terheyden, Patrick, D'Angelo, Sandra P, Shih, Kent C, Lebbé, Céleste, Milella, Michele, Brownell, Isaac, Lewis, Karl D, Lorch, Jochen H, von Heydebreck, Anja, Hennessy, Meliessa, Nghiem, Paul

“…Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an…”
Get full text

Trastuzumab for the Treatment of Salivary Duct Carcinoma by Limaye, Sewanti A., Posner, Marshall R., Krane, Jeffrey F., Fonfria, Maria, Lorch, Jochen H., Dillon, Deborah A., Shreenivas, Aditya V., Tishler, Roy B., Haddad, Robert I.

“…Objectives. Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with high mortality and poor response to treatment. A significant fraction of…”
Get full text

A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma by Hanna, Glenn J., ONeill, Anne, Cutler, Jennifer M., Flynn, Michelle, Vijaykumar, Tushara, Clark, John R., Wirth, Lori J., Lorch, Jochen H., Park, Jong C., Mito, Jeffrey K., Lohr, Jens G., Kaufman, Jeffrey, Burr, Nicole Spardy, Zon, Leonard I., Haddad, Robert I.

“…[Display omitted] •There were no responses; 61% had stable disease (SD) and 28% progression.•One patient remains on drug with SD approaching 1 year.•Half of…”
Get full text

Histological features of BRAF V600E‐mutant anaplastic thyroid carcinoma by Chen, Tiffany Y, Lorch, Jochen H, Wong, Kristine S, Barletta, Justine A

“…Aims Treatment with a BRAF inhibitor, alone or in combination with a MEK inhibitor, may be considered for BRAF‐mutant anaplastic thyroid carcinoma (ATC). The…”
Get full text

The Benefits of Adjuvant Trastuzumab for HER‐2‐Positive Salivary Gland Cancers by Hanna, Glenn J., Bae, Ji Eun, Lorch, Jochen H., Haddad, Robert I., Jo, Vickie Y., Schoenfeld, Jonathan D., Margalit, Danielle N., Tishler, Roy B., Goguen, Laura A., Annino, Donald J., Chau, Nicole G.

“…Background Although high‐grade salivary gland cancers (SGCs) often express androgen receptor (AR) and/or HER‐2/neu, therapeutically targeting these receptors…”
Get full text

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer by Sridharan, Vishwajith, Margalit, Danielle N, Lynch, Stephanie A, Severgnini, Mariano, Zhou, Jun, Chau, Nicole G, Rabinowits, Guilherme, Lorch, Jochen H, Hammerman, Peter S, Hodi, F Stephen, Haddad, Robert I, Tishler, Roy B, Schoenfeld, Jonathan D

“…Background: Preclinical and clinical studies suggest potential synergy between high dose per fraction focal radiation and immunotherapy. However,…”
Get full text

Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma by Hanna, Glenn J., Bae, Ji Eun, Lorch, Jochen H., Schoenfeld, Jonathan D., Margalit, Danielle N., Tishler, Roy B., Haddad, Robert I., Chau, Nicole G.

“…•ACC patients treated within 3 years of recurrent, metastatic diagnosis have poor outcomes.•Disease biology drives prognosis in ACC, despite the use of…”
Get full text

Induction Chemotherapy for Locoregionally Advanced Head and Neck Cancer: Past, Present, Future? by Hanna, Glenn J., Haddad, Robert I., Lorch, Jochen H.

“…The treatment of patients with locoregionally advanced squamous cell cancer of the head and neck is still evolving. Induction chemotherapy (IC) is widely used…”
Get full text

Acupuncture for Chemoradiation Therapy‐Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham‐Controlled Trial by Lu, Weidong, Wayne, Peter M., Davis, Roger B., Buring, Julie E., Li, Hailun, Macklin, Eric A., Lorch, Jochen H., Burke, Elaine, Haddad, Tyler C., Goguen, Laura A., Rosenthal, David S., Tishler, Roy B., Posner, Marshall R., Haddad, Robert I.

“…Introduction. Dysphagia is common in head and neck cancer patients after concurrent chemoradiation therapy (CRT). This study evaluated the feasibility of…”
Get full text

Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma by Rettig, Eleni M, Wentz, Alicia, Posner, Marshall R, Gross, Neil D, Haddad, Robert I, Gillison, Maura L, Fakhry, Carole, Quon, Harry, Sikora, Andrew G, Stott, William J, Lorch, Jochen H, Gourin, Christine G, Guo, Yingshi, Xiao, Weihong, Miles, Brett A, Richmon, Jeremy D, Andersen, Peter E, Misiukiewicz, Krzysztof J, Chung, Christine H, Gerber, Jennifer E, Rajan, Shirani D, D'Souza, Gypsyamber

“…Human papillomavirus-related oropharyngeal carcinoma (HPV-OPC) is increasing in incidence in the United States. Although HPV-OPC has favorable prognosis, 10%…”
Get more information

Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer by Lin, Chi-Iou, PhD, Whang, Edward E., MD, Lorch, Jochen H., MD, Ruan, Daniel T., MD

“…Background We hypothesized that autophagy inhibition would enhance the anticancer efficacy of ret protooncogene–targeted therapy in medullary thyroid cancer…”
Get full text

Frameshift events predict anti–PD-1/L1 response in head and neck cancer by Hanna, Glenn J., Lizotte, Patrick, Cavanaugh, Megan, Kuo, Frank C., Shivdasani, Priyanka, Frieden, Alexander, Chau, Nicole G., Schoenfeld, Jonathan D., Lorch, Jochen H., Uppaluri, Ravindra, MacConaill, Laura E., Haddad, Robert I.

Get full text

Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences by Margalit, Danielle N., MD MPH, Rawal, Bhupendra, MS, Catalano, Paul J., ScD, Haddad, Robert I., MD, Goguen, Laura A., MD, Annino, Donald J., MD DMD, Limaye, Sewanti A., MD MS, Lorch, Jochen H., MD MS, Lavigne, Annie W, Schoenfeld, Jonathan D., MD MPH, Sher, David J., MD, Tishler, Roy B., MD PhD

“…Highlights • Patterns of failure differ when reirradiation is definitive versus postoperative. • After definitive reirradiation, in-field failure is the most…”
Get full text

Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer by LORCH, Jochen H, THOMAS, Tarita O, SCHMOLL, Hans-Joachim

“…The lack of cell-cell adhesion and increased migration are key characteristics of cancer cells. The loss of expression of cell adhesion components and…”
Get full text

Epidermal Growth Factor Receptor Inhibition Promotes Desmosome Assembly and Strengthens Intercellular Adhesion in Squamous Cell Carcinoma Cells by Lorch, Jochen H, Klessner, Jodi, Park, J Ken, Getsios, Spiro, Wu, Yvonne L, Stack, M Sharon, Green, Kathleen J

“…The epidermal growth factor receptor (EGFR) has been proposed as a key modulator of cadherin-containing intercellular junctions, particularly in tumors that…”
Get full text

Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma by Hanna, Glenn J., Kacew, Alec J., Tanguturi, Anusha R., Grote, Hans J., Vergara, Victoria, Brunkhorst, Beatrice, Rabinowits, Guilherme, Thakuria, Manisha, LeBoeuf, Nicole R., Ihling, Christian, DeCaprio, James A., Lorch, Jochen H.

“…Background: Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer. Prior to the advent of immunotherapy, treatment options were limited. In our…”
Get full text